

## [Neostigmine](#)

Essential medicine status

Section:

[5. Medicines for neurological disorders](#) [5.2. Medicines for peripheral nervous system disorders](#) [5.2.2. Medicines for myasthenia gravis](#)

ATC codes: [N07AA01](#)

EMLc

Indication

Myasthenia gravis ICD11 code: [8C70.Z](#)

INN

Neostigmine bromide

Medicine type

Chemical agent

List type

Core

Formulations

**Parenteral > General injections > unspecified:** 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate) ; 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate)

**Oral > Solid > tablet:** 15 mg (neostigmine bromide) (EML)

EML status history

First added in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Neostigmine](#)

DrugBank

[Neostigmine](#)

Summary of evidence and Expert Committee recommendations



Listings for medicines for treatment of myasthenia gravis are duplicated in this section from section 20.